Medtronic’s stent can improve neurological outcome

Global trials have shown that in the treatment of acute ischemic stroke plus Medtronic Solitaire stent in addition to thrombectomy devices can improve the neurological outcome

neuro

In the "New England Journal of Medicine" (NEJM) published online and inthe European Stroke Organization meeting reported on the two global trials show that in the existing drug treatment Canada with Solitaire instrument stand except thrombectomy, can significantly reduce stroke disability. These tests confirmed the same NEJM published in three previous trials of results.

Both trials SOLITAIRE TM FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (except thrombectomy as the acute ischemic stroke major vascular treatments SOLITAIRE TM FR, referred to as the "SWIFT PRIME") and Endovascular Revascularization Solitaire with Versus Best Medical Device Therapy in Anterior Circulation Stroke Within 8 Hours (anterior horn loop stroke within 8 hours using Solitaire equipment for intravascular revascularization vs best medical treatment, referred to as "REVASCAT"), to assess acute ischemia stroke (AIS) patients in the conventional medical treatment (including when using the IV-tPA patients qualify) the addition of Solitaire equipment, which is lighter than stroke-related disability in patients with IV-tPA alone or medical therapy. SWIFT PRIME by the Medtronic (Medtronic plc, NYSE: MDT) sponsorship, while REVASCAT was supported by Medtronic provides a non-limiting funding.

SWIFT PRIME assessment of 196 patients showed that the addition of Solitaire instruments significantly reduce disability after stroke, increasing stroke within 90 days after the functional independence of the number of cases. The trial showed that patients with Solitaire plus instrument, its functional independence recovery rate was significantly higher than that with IV-tPA (60.2% vs. 35.5%, p = 0.0002).
University of California Los Angeles (UCLA) Geffen School of Medicine professor of neurology, director of the UCLA Stroke Center Comprehensive Jeffrey L. Saver, MD, FAHA, FAAN, FANA said: "SWIFT PRIME display, Solitaire device therapy is safe, technically successful It can significantly reduce long-term disability. The therapy marks the beginning of a new era in the treatment of stroke. "

Similarly, REVASCAT (206 patients) showed that the onset of symptoms within eight hours, in medical treatment (including the use of IV-tPA in eligible patients, 70% of enrolled subjects) added with Solitaire treatment equipment Patients recover its functional independence higher than medical therapy alone (43.7% vs. 28.2%), the difference was statistically significant.

SWIFT PRIME and REVASCAT also confirmed that the same three global test published in the NEJM results: Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial (extended thrombolysis for emergency neurological disorder - time intra-arterial, hereinafter referred to as "EXTEND-IA"), Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (endovascular treatment for small core and proximal obstructive ischemic stroke, hereinafter referred to as "ESCAPE") and Multi center Randomized Clinical trial of Endovascular treatment for Acute ischemic Stroke in the Netherlands (endovascular treatment for acute ischemic stroke - Dutch multicenter randomized clinical trial, hereinafter referred to as "MR CLEAN"). These tests have shown that the time delay before treatment can significantly affect the outcome.Compared with the previous test, SWIFT PRIME workflow (from diagnosis to treatment of the entire treatment period) were significantly improved. The trial in seven countries, 39 centers, show a different health care system in a wide range of applicability, as well as fast, efficient stand except thrombectomy of treatment can reach.

 

Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X